Branded

PORTLAND, Ore. — Aisle7 on Thursday announced the launch of Healthnotes Interactions Checker, a next-generation solution simplifying the task of deciding which nutrients positively or negatively interact with the medicines they take. More than half of all Americans take some form of dietary supplement, and an estimated 40% of U.S. adults take both drugs and nutrients as part of their health regimen. Of these, 60% aren’t discussing possible interactions with their physician or pharmacist, Aisle7 noted. 

INDIANAPOLIS — Many physicians in Asia say more information on managing Type 2 diabetes is needed, according to a new poll.

WAUKESHA, Wis. — On Jan. 23, 2014 Hamacher Resource Group will offer its most popular workshop, "How to Grow Sales Within Independent Pharmacy," at its headquarters in Waukesha, Wis., the company announced Wednesday. 

NEW YORK — Noven Pharmaceuticals has launched a new drug for severe hot flashes nationwide, the company said.

The drug maker announced the availability of Brisdelle (paroxetine) capsules in the 7.5-mg strength, the first-ever non-hormonal drug approved by the Food and Drug Administration for moderate to severe hot flashes associated with menopause.

MALVERN, Pa. — Endo Health Solutions will acquire Canadian drug maker Paladin Labs for $1.6 billion, mostly in shares of stock, Endo said Tuesday.

DENVER — Silvergate Pharmaceuticals has launched a new drug for treating high blood pressure in children, the company said Monday.

The drug maker announced the availability of Epaned (enalapril maleate) powder for oral suspension, for treating hypertension in patients older than 1 month. Enalapril is one of the most commonly prescribed medicines in the United States for high blood pressure. Epaned was approved in August 2013 as a flavored liquid solution to appeal to children and others who have difficulty swallowing enalapril tablets.

ATLANTA — Drug maker UCB is seeking approval for one of its drugs as a stand-alone therapy for epilepsy.

The company said Monday that the Food and Drug Administration had accepted its regulatory approval application for Vimpat (lacosamide) for adult epilepsy patients with partial-onset seizures. The drug is already approved as an add-on therapy for partial-onset seizures in patients aged 17 and older.

SILVER SPRING, Md. — The Food and Drug Administration has asked Ariad Pharmaceuticals to suspend marketing and sales of a chemotherapy drug for leukemia due to the risk of life-threatening side effects, the agency said.